Lat­est news on J&J's ma­jor court win; Ukraine's place in biotech; Man­ag­ing ex­pec­ta­tions for AI; Lil­ly ups its RNA ...

4 years ago
Weekly

US judge rules in fa­vor of J&J in con­tro­ver­sial 'Texas two-step' case

4 years ago
Pharma

EMA short­ens time­line for Mod­er­na's Spike­vax Covid boost­er 

4 years ago
Pharma
Coronavirus

Bio­haven con­tin­ues push for oral mi­graine med Nurtec amid new port­fo­lio line up

4 years ago
Pharma
Marketing

FTC wants to know: How are PBMs af­fect­ing drug af­ford­abil­i­ty and ac­cess?

4 years ago
Pharma

J&J, drug dis­trib­u­tors sign off on a mam­moth $26B opi­oid set­tle­ment with 46 states

4 years ago
Pharma

Glax­o­SmithK­line am­pli­fies the agony of ‘la cule­bril­la’ to raise shin­gles aware­ness with Span­ish speak­ers

4 years ago
Pharma
Marketing

More than 100 House and Sen­ate Re­pub­li­cans call on new FDA com­mish to re­verse or­der on mail-or­der abor­tion pills

4 years ago
FDA+

Covid-19 roundup: Val­ne­va runs in­to EMA ques­tions, still ex­pects March au­tho­riza­tion; Cana­da ap­proves first ...

4 years ago
Coronavirus

Russ­ian in­va­sion of Ukraine threat­ens hun­dreds of clin­i­cal tri­als

4 years ago
R&D

In two sep­a­rate moves, Bio­haven seeks to re­pur­pose failed Bris­tol My­ers/Roche Duchenne drug while buy­ing out small ...

4 years ago
Deals

Japan, UK pledge new funds to CEPI's $3.5B pan­dem­ic pre­pared­ness plan, with eye to­ward fu­ture out­breaks

4 years ago
Coronavirus

Watch out, No­var­tis: Eli Lil­ly, Boehringer In­gel­heim notch broad heart fail­ure OK for Jar­diance

4 years ago
Pharma
FDA+

As­traZeneca's Evusheld and GSK's sotro­vimab lose ef­fi­ca­cy against Omi­cron's sub­vari­ants

4 years ago
FDA+
Coronavirus

Or­p­hazyme runs in­to an­oth­er set­back as Eu­rope ap­pears un­like­ly to ap­prove its FDA-re­ject­ed drug

4 years ago
FDA+

Till­man Gern­gross leads a pack of biotech CEOs out the door; With eyes on pipeline ex­pan­sion, Po­sei­da woos a gene ...

4 years ago
Peer Review

For biotech, Russ­ian in­va­sion of Ukraine threat­ens to up­end a slew of ear­ly-stage R&D projects

4 years ago
R&D

Sanofi sig­nals a big in­ter­est in on­col­o­gy as it adds a can­cer R&D star to the board

4 years ago
Pharma

Last year was one of the 'most event­ful in US biosim­i­lars his­to­ry,' but these an­a­lysts say 2022 should be 'a turn­ing ...

4 years ago
Pharma

Ab­b­Vie slams the pen­sion door to new hires as Big Phar­ma hold­outs fi­nal­ly join the mi­gra­tion to 401Ks

4 years ago
Pharma

Bio­Marin ‘turn­ing the cor­ner’ on prof­its with op­ti­mism on Vox­zo­go, Roc­ta­vian — but ques­tions re­main

4 years ago
Pharma
Marketing

Pub­lic Cit­i­zen picks apart Cures 2.0 draft leg­is­la­tion, crit­i­ciz­ing sev­er­al RWE pro­vi­sions

4 years ago
FDA+

On a roll, Re­ci­pharm wraps up its sec­ond and third CD­MO ac­qui­si­tions this month

4 years ago
Pharma
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Scot­tish gov­ern­ment in­vests $27M in Val­neva's Covid-19 man­u­fac­tur­ing; Mod­er­na ...

4 years ago
Manufacturing
First page Previous page 576577578579580581582 Next page Last page
A service from the Financial Times